個人檔案
學歷
- 2002 臺大醫學院藥理學研究所博士
- 1994 臺北醫學大學醫學研究所碩士
經歷
- 2023.03- 臺北醫學大學醫學科技學院院長
- 2020-2023 臺北醫學大學醫學科技學院副院長
- 2019-2022 臺北醫學大學新藥研發產業博士學位學程主任
- 2018- 臺北醫學大學癌症生物學與藥物研發研究所教授
- 2017- 臺北醫學大學生技醫療產業研發博士學位學程教授
- 2016-2018 臺北醫學大學癌症生物學與藥物研發博士學位學程教授
- 2013-2016 臺北醫學大學癌症生物學與藥物研發博士學位學程副教授
- 2008-2013 臺北醫學大學藥理學科助理教授
- 2009-2013 國家衛生研究院助理研究員
- 2007-2009 臺大醫學院助研究員
- 2002-2007 臺大醫學院博士後研究
- 1994-1998 長庚大學醫學系助教
獎項
- 2019 臺北醫學大學單一研究計畫經費獎
研究興趣
- 藥物研發
- 疾病動物模式
- 藥理藥效學
相關連結
指紋
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
-
Artificial intelligence-driven drug discovery: a new era in therapeutic innovation
Swee, Q. Y., Law, S. H., Tu, H. J., Pan, S. L., Hsu, K. C., HuangFu, W. C., Wu, C. J., Tan, E. W. & Goh, B. H., 8月 2026, 於: Bioorganic and Medicinal Chemistry. 139, 118671.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Consensus Pharmacological Interactions for PLK2 Inhibitor Identification in Colorectal Cancer Treatment
Wu, Y. W., Yang, C. L., Lin, T. E., Yeh, Y. H., Fang-Chin, Y. T., Sung, T. Y., Yen, S. C., Hsieh, J. H., Chung, C. C., Pan, S. L. & Hsu, K. C., 1月 12 2026, 於: Journal of Chemical Information and Modeling. 66, 1, p. 577-590 14 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Identification and biological evaluation of benzimidazole-based compounds as novel TGFβR1 inhibitors
Tseng, H. J., Wu, Y. W., Chen, Y. L., Lin, T. E., Fang-Chin, Y. T., Wu, Y. L., Sung, T. Y., Yen, S. C., Hsieh, J. H., Hsu, K. C. & Pan, S. L., 2026, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 41, 1, 2600746.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer
Chung, C. H., Hsu, K. C., Huang, M. M., Tu, H. J., Pan, S. L. & Chao, M. W., 12月 31 2025, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 40, 1, 2538673.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 連結會在新分頁中打開 引文 斯高帕斯（Scopus） -
Exploring diarylheptanoid derivatives to target LIMK1 as potential agents against colorectal cancer
Chen, L. C., Chang, T. C., Tseng, H. J., Chu, J. C., Huang, Y. Y., Peng, H. Y., Kuo, Y. C., Wu, Y. W., Lin, T. E., Yen, S. C., Hsu, K. C., Huang, W. J. & Pan, S. L., 12月 2025, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 40, 1, p. 2583826 2583826.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取
資料集
-
Additional file 1: of The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H.-J. (Contributor), Lin, Y.-J. (Contributor), Chao, M.-W. (Contributor), Sung, T.-Y. (Contributor), Wu, Y.-W. (Contributor), Chen, Y.-Y. (Contributor), Lin, M.-H. (Contributor), Liou, J.-P. (Contributor), Pan, S.-L. (Contributor) & Yang, C.-R. (Contributor), Unknown Publisher, 12月 29 2018
DOI: 10.6084/m9.figshare.7531874.v1, https://springernature.figshare.com/articles/Additional_file_1_of_The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/7531874/1
資料集: Dataset
-
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chang, L.-H. (Contributor), Liou, J.-P. (Creator), Lai, M.-J. (Contributor), Chang, C.-D. (Contributor), Tu, H.-J. (Contributor), Chao, M.-W. (Contributor), Pan, S.-L. (Contributor), Chen, Y.-Y. (Creator) & Teng, C.-M. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://doi.org/10.6084%2Fm9.figshare.8202902.v1
資料集: Dataset
-
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
資料集: Dataset
-
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
資料集: Dataset